Oral solution and powder to liquid compositions of balsalazide
US12053447B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 25, 2019 |
| Grant date | Aug 6, 2024 |
| Priority date | — |
| Expiry date | Nov 27, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition for preparation of an orally administered liquid solution containing a therapeutically sufficient dose of dissolved balsalazide. The composition further comprises three artificial sweeteners comprising sucralose, acesulfame potassium and ammonium glycyrrhizinate that unexpectedly mitigate the bitter attributes of the orally administered liquid balsalazide solution that would otherwise render the solution unpalatable. More particularly, the present disclosure relates to a composition of the three artificial sweeteners and a therapeutically sufficient dose of balsalazide for the treatment of bowel disorders such as ulcerative colitis. Unit dose sachets of balsalazide disodium 750 mg and 2,250 mg of powder to oral solution are also disclosed. The disclosure further provides a kit including a dissolvable solid phase composition of the three artificial sweeteners and dissolvable solid phase therapeutically sufficient dose of balsalazide and further comprising a therapeutic dose of a probiotic (bacillus) to enhance the azoreduction of the balsalazide in the colon.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.